Cover Image
Annual Information Service

Biosimilar Index: Tracking the Biosimilar Development Landscape

Published by FirstWord Product code 298599
Published annual subscription Content info
Please contact us using the inquiry form for pricing information.
Back to Top
Biosimilar Index: Tracking the Biosimilar Development Landscape
Published: annual subscription Content info:

A new force in biosimilar and NCB drug and market tracking

FirstView's Biosimilar Index is a new, comprehensive drug intelligence service which provides a robust, dynamically updated and highly-detailed insight into the status of leading biosimilar and NCB assets in development worldwide. Exhaustively referenced and sourced, it is one of the most comprehensive analyses of its type providing both on-going tracking of development and interpretation of the commercial and clinical significance.

Two class beating services in one subscription!

Biosimilar Index: Pipeline Database

The Biosimilars Index: Pipeline Database is checked daily. When a significant event happens, the database is updated, thereby ensuring you're up to date with current market dynamics. The database is provided as a dynamic MS Excel™ file with complete data and filter analysis tools included.

Available 24/7 through a secure password protected site, there are no limits on how frequently you can download the XLS file. Having access to the database enables you to see the whole biosimilar and NCB landscape across multiple classes and geographies

Essential details covered in the database include:

  • Brand name(s) of reference products
  • Indications and reported sales for the reference product
  • Originator company
  • Biosimilars development company
  • HQ location of development company
  • Therapy class
  • Key indication(s)
  • Mode of application and route of administration
  • Clinical trials status
  • Global marketing status
  • Marketing agreements and licensing opportunities

Powerful data with intuitive analysis tools

With Biosimilars Index: Pipeline Database at hand, you can effortlessly compare and contrast biosimilars in development by country, originator company, stage of development, condition and therapeutic area. The data is provided in MS Excel™ and comes with filters and search built in. The data can easily be exported to your own analytics package or data visualisation platform.

Biosimilar Index: Landscape Review

What's hot and what's not? The biosimilars sector is constantly evolving. Important research progress, commercial deals and product launches are regularly announced. The Biosimilar Index: Landscape Review strips away market rumour and speculation to tell you exactly what has happened and why it is important.

Published quarterly, the Review is based on the daily-updated research in the Biosimilar Index: Pipeline Database, enhanced by critical insights and understanding from biosimilars experts.

The benefits and features of the Biosimilar Index: Landscape Review...

  • Includes essential structured data including
    • Sales data for reference products
    • Current and future market milestones
    • Individual single view analysis for leading products
    • Clinical trial activities and flow charts of development phase.
  • The service draws on a wide-range of reliable information sources such as clinical trial registries, company communications, conference proceedings, broker analysis and social media.
  • Includes powerful interpretation and analysis by knowledgeable experts to ensure that developments are scrutinised and the implications highlighted.
  • Presented in MS PowerPoint™ to bring clarity to the extensive charting and tables provided which can be incorporated into your own presentations

Key benefits and features:

With Biosimilar Index you can...

  • Understand the biosimilar and NCB development landscape through comprehensive coverage of the pipelines of all major biosimilar developers worldwide
  • Drill down to discover the levels of potential biosimilar competition by therapy area, drug class status and geography
  • Establish the level of biosimilar competition for leading biologic brands
  • Learn which biosimilar developers are potential future competitors or collaborators
  • Identify the biosimilar and NCB portfolios of over 130 companies and discover the leaders in product development for which products/therapy areas
  • Know where the development hotspots are and what research is taking place.

The Biosimilar Index is feature rich...

  • Includes both structured data and commercial interpretation
  • The Biosimilar Index: Pipeline Database covers all significant biosimilar products and is updated daily. Available 24/7 in MS Excel™ with unlimited downloads which can be incorporated into your own analytics package or visualisation software
  • The Biosimilar Index: Landscape Review provides and insightful quarterly analysis which identifies the developments that are really important
  • Biosimilar Index is Informed by a wide-range of respected sources with expert internal and external inputs and oversight

A service for the whole industry

Whether you work in big pharma, a biosimilars development company, a clinical service organisation, a regulatory body or in commercial investment and finance, the Biosimilar Index provides a clear window on the world of biosimilar drugs and their developers.

With the Biosimilar Index you are always in the know!

Table of Contents

Table of Contents


Executive summary

Reference medicinal product data

Market milestones; Q1 2013 - Q1 2014

Potential future milestones; Q2 2014 - Q4 2014

Biosimilar programme analysis

  • Pipeline summary by molecule
  • Clinical trials by molecule


  • Data sources
  • Definitions and terminology
  • Disclaimer

[139 slides]

List of Companies

  • AbbVie
  • Idec Pharmaceuticals
  • Sanofi
  • Genentech
  • Centocor
  • Immunex
  • Amgen Genentech
  • Kirin Holdings
  • Novo Nordisk
  • Biogen Idec
  • Eli Lilly
  • Sanofi
  • Novo Nordisk
Back to Top